UK-based digital health company MedPal AI ( ) has commenced trading on the Frankfurt Stock Exchange, adding a secondary listing under the ticker Z1N alongside its primary AIM listing in London.
The move coincides with the launch of a German-language version of the company’s AI wellness app, marking the beginning of a targeted expansion into Europe’s largest economy. Chief executive Jason Drummond called the listing “an important milestone,” citing access to Germany’s fast-growing retail investor base and the strategic value of increased visibility.
Germany’s retail investment market reached a record 14.1 million participants in 2025, driven by younger, tech-savvy investors. The rise of low-cost trading platforms has further eased access to dual-listed shares, making Frankfurt a favourable venue for growth-focused firms like MedPal.
Beyond capital markets, the company plans to roll out additional services in Germany over the next six months, targeting a digital health sector forecast to grow at over 20 per cent annually through to 2030. An investor event in March is expected to deepen engagement with the German financial community.
While the expansion brings increased regulatory complexity, MedPal views the dual listing as both a financial and operational gateway to the continent, positioning itself as a digital health provider embedded in the markets it aims to serve.
View from Vox:
MedPal’s Frankfurt listing is more than a financial manoeuvre; it’s a calculated move into a high-growth market at the intersection of health-tech and retail investment.
By pairing the listing with a localised app launch, the company signals genuine intent to operate, not just trade, in Germany. With a booming health-tech sector and a retail investor base increasingly drawn to accessible, mission-driven tech companies, MedPal is positioning itself well. If MedPal can scale effectively, this could mark the start of an exciting European growth story.